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The p53 protein has emerged as a key tumor suppressor at
the crossroads of cellular stress-response pathways. In response
to a stress signal, such as DNA damage, hypoxia, or activated
oncogenes, p53 is activated and functions as a sequence-specific transcription factor regulating a plethora of downstream
target genes, which mediate various p53 functions, such as cell
cycle arrest, apoptosis, and senescence (1, 2). However,
although many target genes have been identified, those
involved in p53-dependent cellular senescence are still poorly
understood (3). Thus, identification of novel p53 targets
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involved in senescence is of great interest because cellular
senescence may be as important as apoptosis in mediating p53dependent tumor suppression (4).
Cellular senescence was first described as “replicative senescence” because of a limited life span of human diploid fibroblasts in vitro (5), which is triggered by DNA damage signals
originating from progressive telomere shortening during cell
divisions (6). Senescent cells are characterized by enlarged cell
size, flattened morphology, inability to synthesize DNA, and
expression of the biomarker, senescence-associated (SA)2
␤-galactosidase (7). Recent studies have shown that various
stress signals, such as aberrant oncogene activity (8) and cancer
chemotherapeutic drugs (9, 10), are able to initiate senescencelike phenotypes (“premature senescence”). It has been shown
that cellular senescence utilizes both p53 and p16 pathways in
human cells (8, 11). p53 up-regulates p21, a pleiotropic inhibitor of cyclin/cyclin-dependent kinases, which initiates growth
arrest by preventing pRb phosphorylation by cyclin-dependent
kinases. In contrast, p16 specifically inhibits cyclin-dependent
kinase 4/6 to prevent pRb phosphorylation (12). In addition, a
recent report showed that p53 selectively cooperates with p130,
a member of the pRb family, to induce premature senescence
when the p16/pRb pathway is disrupted (13). Moreover, DNA
damage promotes cancer cell senescence primarily through
p130 (14). Interestingly, lack of p53 or p21 diminishes but does
not abrogate DNA damage-induced premature senescence in
tumor cells (15), which suggests that senescence can occur
through a p53-independent mechanism or an unknown p53
target gene.
DEC1 (differentiated embryo-chondrocyte expressed gene
1), also called STRA13 (stimulated with retinoic acid 13) in
mouse and SHARP2 (enhancer of split and hairy related protein 2) in rat, along with DEC2, belongs to a new subfamily of
basic helix-loop-helix (bHLH) transcription factors (16).
DEC1 functions as a transcription repressor by directly binding
to class B E-boxes (17) by interacting with components of the
basal transcription machinery, such as TFIIB, TBP, and TFIID
(18, 19), or by recruiting a histone deacetylase corepressor com2

The abbreviations used are: SA, senescence-associated; HA, hemagglutinin;
siRNA, small interfering RNA; nt, nucleotide; ChIP, chromatin immunoprecipitation; p53-RE, p53-responsive element; bHLH, basic helix-loop-helix;
BrdUrd, bromodeoxyuridine; PI, propidium iodide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; KD, knockdown; pRb, retinoblastom
protein.
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Cellular senescence plays an important role in tumor suppression. p53 tumor suppressor has been reported to be crucial in
cellular senescence. However, the underlying mechanism is
poorly understood. In this regard, a cDNA microarray assay was
performed to identify p53 targets involved in senescence.
Among the many candidates is DEC1, a basic helix-loop-helix
transcription factor that has been recently shown to be up-regulated in K-ras-induced premature senescence. However, it is
not clear whether DEC1 is capable of inducing senescence. Here,
we found that DEC1 is a novel target gene of the p53 family and
mediates p53-dependent premature senescence. Specifically,
we showed that DEC1 is induced by the p53 family and DNA
damage in a p53-dependent manner. We also found that the p53
family proteins bind to, and activate, the promoter of the DEC1
gene. In addition, we showed that overexpression of DEC1
induces G1 arrest and promotes senescence. Moreover, we
found that targeting endogenous DEC1 attenuates p53-mediated premature senescence in response to DNA damage. Furthermore, overexpression of DEC1 induces cellular senescence
in p53-knockdown cells, albeit to a lesser extent. Finally, we
showed that DEC1-induced senescence is p21-independent.
Taken together, our data provided strong evidence that DEC1 is
one of the effectors downstream of p53 to promote premature
senescence.

DEC1 Is a Mediator of p53-dependent Premature Senescence

EXPERIMENTAL PROCEDURES
Plasmids—FLAG-tagged wild-type DEC1 and untagged
mutant DEC1 cDNAs in pCMV and pcDNA4 expression vectors were described previously (17, 21). To generate untagged
wild-type DEC1 in pcDNA4 for tetracycline-inducible expression (Invitrogen), the cDNA fragment was amplified from
FLAG-tagged wild-type DEC1 cDNA (17) with forward primer,
5⬘-AGGAATTCACCATGGAGCGGATCCCCAGCG-3⬘, and
reverse primer, 5⬘-AGTCTAGAAGGAAGGAAAGCAAAGCAG-3⬘. To generate a construct for the inducible expression of
DEC1 siRNA, two oligonucleotides, 5⬘-GATCCCCGCACTAACAAACCTAATTGTTCAAGAGACAATTAGGTTTGTTAGTGCTTTTTGGAAA-3⬘ and 5⬘-AGCTTTTCCAAAAAGCACTAACAAACCTAATTGTCTCTTGAACAATTAGGTTTGTTAGTGCGGG-3⬘, were designed to target the
DEC1 fourth exon (in boldface). The oligonucleotides were
annealed and cloned into pBabe-H1, a pol III promoter-driven
short hairpin RNA expression vector with a tetracycline operator sequence inserted before the transcriptional starting site
(23). The resulting vector was designated pBabe-H1-siDEC1.
To generate a construct that stably expresses p21 siRNA, one
pair of oligonucleotides with the siRNA targeting region as
shown in boldface, sense, 5⬘-TCGAGGTCCGCCTCCTCATCCCGTGTTCTTCAAGAGAGAACACGGGATGAGGAGGCTTTTTG-3⬘, and antisense, 5⬘-GATCCAAAAAGCCTCCTCATCCCGTGTTCTCTCTTGAAGAACACGGGATGAGGAGGCGGACC-3⬘, were annealed and cloned into
pBabe-U6 at BamHI and XhoI sites, a pol III promoter-driven
vector as described previously (24). The resulting vector was
named pBabe-U6-sip21. The construct expressing p53 siRNA
was described previously (25).
To generate a luciferase reporter under the control of the
DEC1 promoter (nt ⫺4468 to ⫹170), two genomic DNA fragFEBRUARY 1, 2008 • VOLUME 283 • NUMBER 5

ments were amplified from MCF7 cells and ligated together
through a common EcoRV site. The first pair of primers are as
follows: forward primer, DEC1-KpnI-4468 (5⬘-ATGGTACCCAGGCTGGAGTACAGTGGCATGATC-3⬘), and reverse
primer, DEC1-EcoRV-As (5⬘-ACGCCCACAACTTGCTTGCTCAGATATCAC-3⬘). The second pair of primers are as follows: forward primer, DEC1-EcoRV-S (5⬘-AGTGATATCTGAGCAAGCAAGTTGTGGGCATG-3⬘), and reverse primer,
DEC1-XhoI (5⬘-AACTCGAGCCGCAGATGTTCCTCTGAGTCTGAG-3⬘). To generate a DEC1 promoter lacking the
potential p53-RE, a fragment from nt ⫺2343 to ⫹170 was
amplified with forward primer, DEC1-KpnI-2343 (5⬘-TTGGTACCCACACAATGAAGCAGGTCGCCC-3⬘), and reverse
primer, DEC1-XhoI as shown above.
Cell Lines—MCF7, RKO, MCF7-p53-KD, and RKO-p53-KD
were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum at 37 °C with 5% CO2.
H1299 cell lines that inducibly express p53 family proteins were
described previously (26 –28). MCF7-p53-KD and RKOp53-KD are derivatives of MCF7 and RKO, respectively, in
which p53 was stably knocked down by RNA interference.
MCF7-TR-7, which expresses the tetracycline repressor, was
generated in our laboratory. To generate cell lines that inducibly express wild-type or various mutant DEC1 proteins,
MCF7-TR-7 cells were transfected with pcDNA4-DEC1,
pcDNA4-DEC1-M, or pcDNA4-DEC1-R58P and selected with
medium containing 200 g/ml Zeocin. To generate cell lines in
which DEC1 is inducibly knocked down, MCF7-TR-7 cells
were transfected with pBabe-H1-siDEC1 and selected with 0.5
g/ml puromycin. MCF7 cell lines, in which p53 or p21 was
stably knocked down and DEC1 is inducibly expressed, were
generated by transfecting pBabe-U6-sip53 or pBabe-U6-sip21
into M7-DEC1-16 as generated above, and cells were selected
with 0.5 g/ml puromycin.
Affymetrix GeneChip Assay and Northern Blot Analysis—Total RNAs were isolated by using TRIzol reagent (Invitrogen).
The U133-plus GeneChip was purchased from Affymetrix.
GeneChip analysis was performed according to the manufacturer’s instruction. Northern blot analysis and preparation of
p21 and GAPDH probes were described previously (29). Wildtype DEC1 cDNA was used as probe and amplified as described
above.
Luciferase Reporter Assay—The dual luciferase assay was
performed in triplicate according to the manufacturer’s
instruction (Promega). Briefly, 0.25 g of a luciferase reporter,
0.25 g of empty pcDNA3, or pcDNA3 that expresses p53 or
p53(R249S) and 9 ng of an internal control Renilla luciferase
assay vector pRL-CMV (Promega) were transfected into p53null H1299 cells by using the ESCORT V transfection reagent
according to the manufacturer’s instruction (Sigma). Cells were
seeded at 2 ⫻ 104 per well in 24-well plates 24 h before transfection. 18 h post-transfection, luciferase activity was measured
with the dual luciferase kit and Turner Designs luminometer.
The fold change in relative luciferase activity is a product of the
luciferase activity induced by a p53 family protein divided by
that induced by an empty pcDNA3 vector.
Chromatin Immunoprecipitation (ChIP) Assay—ChIP assay
was performed as described previously (24). The binding of a
JOURNAL OF BIOLOGICAL CHEMISTRY
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plex (20). Interestingly, DEC1 is implicated in cell cycle regulation, differentiation, and apoptosis in response to various extracellular stimuli, including hypoxia, serum starvation, and
retinoid acid (16). Indeed, overexpression of DEC1 inhibits cell
proliferation in multiple cell types, such as NIH3T3 (20), HEK293T (21), and HaCat cells (18). However, the mechanism by
which DEC1 regulates cell proliferation is not clear. Furthermore, a recent report shows that premature senescence
induced by oncogene K-rasV12 correlates with DEC1 up-regulation (22), but it is not clear whether DEC1 is capable of inducing senescence.
In this study, we identified DEC1 as a direct target of the p53
family. We found that DEC1 is induced by p53 family proteins
and DNA damage in a p53-dependent manner. In addition, we
identified a potential p53-binding site in the promoter of the
DEC1 gene. Moreover, we found that overexpression of DEC1
alone elicits premature senescence, and knockdown of DEC1
attenuates DNA damage-induced premature senescence. Furthermore, we found that overexpression of DEC1 is able to initiate cellular senescence in p53-knockdown cells albeit to a
lesser extent, and DEC1-induced senescence is p21-independent. Taken together, our data strongly indicate that DEC1 is one
of the mediators downstream of p53 to promote premature
senescence.

DEC1 Is a Mediator of p53-dependent Premature Senescence
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for 15 min. The harvested living cells
were fixed in precooled (⫺20 °C) ethanol (70%) overnight followed by
BrdUrd/PI staining. Briefly, after centrifugation, the cells were treated with
1 ml of 2 N HCl/Triton X-100 for 30
min at room temperature, centrifuged, resuspended in 1 ml of 0.1 M
Na2B4O7 (pH 8.5) to neutralize the
sample, and incubated with fluorescein isothiocyanate-labeled antiBrdUrd antibody (BD Biosciences) for
30 min at room temperature followed
by addition of 300 l of phosphatebuffered saline/PI (50 g/ml). Samples
were analyzed by fluorescence-activated cell sorting (BD Biosciences).
Western Blot Analysis—Whole
cell extracts were prepared with 2⫻
SDS sample buffer and boiled for 5
min at 95 °C. The antibody against
DEC1 was generated in rabbit (21).
Antibodies against p53, p21, p130,
and HA epitope were purchased
from Santa Cruz Biotechnology.
Anti-actin, and mouse IgG, and
rabbit IgG were purchased from
Sigma. Anti-Myc epitope was purFIGURE 1. DEC1 is up-regulated by the p53 family. A, DEC1 is induced by p53, p63␤, p63␥, p73␤, and ⌬Np73␤ chased from Abcam. Anti-Rb (clone
but not mutant p53(R249S). Northern blots were prepared with RNAs purified from H1299 cells that were XZ-77) was used as described (31).
uninduced (⫺) or induced (⫹) to express various p53 family proteins as shown at the top of the figure. The blots
SA-␤-Galactosidase Staining Aswere probed with cDNAs derived from the DEC1, p21, and GAPDH genes, respectively. GAPDH was measured as
a loading control. B, DEC1 is induced upon DNA damage in a p53-dependent manner. Northern blots were say—This assay was performed as
prepared with RNAs purified from MCF7, MCF7-p53-KD, RKO, and RKO-p53-KD cells that were untreated (⫺) or described previously (7). Cells were
treated (⫹) with 0.35 g/ml doxorubicin (Dox) for 24 h. The blots were analyzed as in A. C, DEC1 expression is
up-regulated by p53 family proteins. Western blots were prepared with extracts from H1299 cells that were washed with 1⫻ phosphate-buffuninduced (⫺) or induced (⫹) to express various p53 family proteins as shown at the top of the figure. p53 and ered saline and fixed with 2% formmutant p53(R249S) were detected by anti-p53. The Myc-tagged p63 proteins were detected by anti-Myc aldehyde, 0.2% glutaraldehyde for
epitope, and the HA-tagged p73 proteins were detected by anti-HA epitope. DEC1, p21, and actin were
detected by their respective antibodies. The level of actin was measured as a loading control. D, DEC1 expres- 10 –15 min at room temperature.
sion is up-regulated by DNA damage in a p53-dependent manner. Western blots were prepared with extracts Cells were then washed twice with
from MCF7, MCF7-p53-KD, RKO, and RKO-p53-KD cells that were untreated (⫺) or treated (⫹) with 0.35 g/ml
1⫻ phosphate-buffered saline and
doxorubicin for 24 h. The blots were analyzed as in C.
stained with fresh SA-␤-galactosidp53 family protein to the DEC1 promoter was detected with ase staining solution at 37 °C without CO2. The SA-␤-galactoforward primer, 5⬘-GGTTCAAGCGATTCTCCTGCCTC-3⬘, sidase staining solution contains 1 mg/ml 5-bromo-4-chloro-3and reverse primer, 5⬘-CAGTGGCTCACGCCTGTAATCCT-3⬘. indolyl-␤-D-galactopyranoside, 40 mM citric acid/sodium
Primers that were used to amplify the p53-responsive element 1 phosphate (pH 6.0), 5 mM potassium ferrocyanide, 5 mM potaswithin the p21 promoter were described previously (24). Prim- sium ferricyanide, 150 mM NaCl, and 2 mM MgCl2.
ers for the amplification of the GAPDH promoter were used as
RESULTS
described previously (30).
Growth Rate and Colony Formation Assay—For growth rate
Identification of DEC1 as a Novel Target Gene of the p53
analysis, cells were seeded at 1 ⫻ 104 per well in 6-well plates Family—To identify novel genes regulated by p53, an
with or without doxycycline (an analog of tetracycline) in trip- Affymetrix GeneChip assay was performed with U133 plus
licate. Attached cells were counted at the indicated times. For Chips and RNAs purified from MCF7 cells uninduced or
colony formation assay, cells were seeded at 500 per well in induced to express p53. Many known p53 target genes, such as
6-well plates with or without doxycycline in triplicate. Colonies MDM2, p21, and PIG3, and several novel targets, such as DNA
were fixed with methanol:glacial acetic acid (7:1), washed in polymerase  (pol H) (32) and myosin VI (33), were found to be
H2O, and stained with 0.02% crystal violet.
highly induced by p53. We also found that DEC1 was induced
DNA Histogram Analysis—Cells were seeded at 5 ⫻ 104 per by p53. To confirm this, Northern blot analysis was performed.
100-mm plate with or without doxycycline in triplicate. Cells We showed that DEC1 was induced by p53 but not mutant
were incubated with 20 M BrdUrd (Sigma) at 37 °C, 5% CO2 p53(R249S) in H1299 cells (Fig. 1A, DEC1 panel). Similarly,
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p53-proficient (MCF7 and RKO)
but not p53-knockdown (MCF7p53-KD and RKO-p53-KD) cells
(Fig. 1D, DEC1 and p21 panels).
As a transcription factor, p53 regulates gene expression by directly
binding to a p53-responsive element (p53-RE) in the target gene.
The consensus p53-RE is composed
of two half-sites (RRRC(A/T)(A/
T)GYYY, where R represents purine
and Y pyrimidine) separated by up
to 13 nt (37). Thus, if DEC1 is a
direct p53 target, one or more p53REs should exist in the DEC1 gene.
To test this, we analyzed the
genomic locus of the DEC1 gene
and found one potential p53-binding site located between nucleotides
⫺4211 to ⫺4181, with the sequence
of AGGCAAGTTTTTAAATTTCAGGTCATGATC (Fig. 2A). Upon
FIGURE 2. Identification of a potential p53-responsive element (p53-RE) in the DEC1 gene. A, schematic alignment with the consensus
presentation of the DEC1 genomic structure and luciferase (Luc) reporter constructs along with a potential sequence, this p53-RE contains two
p53-RE located at nt ⫺4211 to ⫺4181 in the promoter of the DEC1 gene. B, potential p53-RE in the DEC1 gene
is responsive to p53, p63␤, and p73␤ but not to mutant p53(R249S). The luciferase assay was performed as mismatches at noncritical positions
described under “Experimental Procedures.” C, schematic presentation of the DEC1, p21, and GAPDH promot- (Fig. 2A, mismatches in lowercase
ers with the location of the potential p53-REs and PCR primers used for ChIP assays. D–F, p53, p63␤, and p73␤ and core sequences in boldface).
bind to the p53-RE in vivo. See details in the text.
To determine whether this
p53-RE is responsive to a p53 family
p21, a well characterized p53 target, was up-regulated by p53 protein, two DNA fragments from the DEC1 promoter, in
but not mutant p53(R249S) (Fig. 1A, p21 panel). Because the which the p53-RE is retained (⫺4468/⫹170) or deleted
p53 family proteins, p63 and p73, have been shown to activate (⫺2343/⫹170), were cloned into pGL2-basic luciferase
some p53-responsive genes, including p21 (34), we examined reporter. The resulting vectors were designated pGL2-DEC1whether DEC1 is induced by p63 and p73. We found that both 4468 and pGL2-DEC1-2343, respectively (Fig. 2A). Next, lucifDEC1 and p21 were induced in H1299 cells by p63␤, p63␥, erase reporter assay was performed and showed that p53, p63␤,
p73␤, and ⌬Np73␤ (Fig. 1A, DEC1 and p21 panels).
and p73␤ were able to increase the luciferase activity for pGL2DNA damage stabilizes and activates p53, leading to induc- DEC1-4468 but not pGL2-DEC1-2343 (Fig. 2B). In contrast,
tion of p53 target genes (35). If DEC1 is a true p53 target, it mutant p53(R249S) was inert (Fig. 2B). As a positive control,
would be induced by DNA damage in cells that contain an the p21 promoter was highly increased by p53 but not
endogenous wild-type p53 gene. To this end, MCF7, MCF7- p53(R249S) (data not shown). These data suggest that the
p53-KD, RKO, and RKO-p53-KD cells were untreated or p53-RE in the DEC1 gene is responsive to p53.
treated with doxorubicin, an inhibitor of topoisomerase II that
To further examine whether a p53 family protein can bind to
can induce DNA double strand breaks (36). We found that the p53-RE in the DEC1 gene in vivo, ChIP assay was performed
DEC1 was induced by doxorubicin in MCF7 and RKO cells (Fig. with primers shown in Fig. 2C (left panel). The binding of the
1B, DEC1 panel). Similarly, p21 was induced (Fig. 1B, p21 p53 family proteins to the p53-RE in the p21 promoter was
panel). In contrast, little if any DEC1 or p21 was detected in determined as a positive control (Fig. 2C, middle panel). Addip53-knockdown MCF7 and RKO cells (Fig. 1B, DEC1 and p21 tionally, a region within the promoter of the GAPDH gene was
panels).
amplified as a control for nonspecific binding (Fig. 2C, right
Next, we examined whether an increase in DEC1 transcript panel). To test the binding of p53 to the DEC1 promoter, MCF7
correlates with an increase in DEC1 protein. We found that cells were untreated or treated with doxorubicin to activate
DEC1 was up-regulated in H1299 cells by p53, p63␣, p63␤, p53, and the p53-DNA complexes were immunoprecipitated
⌬Np63␤, p63␥, ⌬Np63␥, p73␣, ⌬Np73␣, p73␤, and ⌬Np73␤ with anti-p53 antibody or mouse IgG as a control. We found
but not mutant p53(R249S) and ⌬Np63␣ (Fig. 1C, DEC1 panel). that the captured fragments containing the p53-RE were signifThe expression of p21 was measured as a positive control and icantly increased upon induction of p53 by DNA damage (Fig.
found to be induced by p53, p63␣, p63␤, ⌬Np63␤, p63␥, p73␣, 2D, DEC1 panel). Similarly, p53 bound to the p53-RE1 in the
p73␤, and ⌬Np73␤ but not mutant p53(R249S), ⌬Np63␣, p21 gene in response to DNA damage (Fig. 2E, p21 panel).
⌬Np63␥, and ⌬Np73␣ (Fig. 1C, p21 panel). In addition, we However, no fragments were enriched by control IgG (Fig. 2D,
showed that like p21, DEC1 was induced by DNA damage in DEC1 and p21 panels). Furthermore, the GAPDH promoter
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FIGURE 3. Overexpression of DEC1, but not mutant DEC1-M and DEC1-R58P, inhibits cell proliferation and induces cell cycle arrest in G1. A, left and
middle panels, generation of MCF7 cell lines that inducibly express DEC1, mutant DEC1-M, or DEC1-R58P. The levels of DEC1, DEC1-M, and DEC1-R58P were
quantified with anti-DEC1. Right panel, level of DNA damage-induced DEC1 is comparable with that of ectopic-expressed DEC1. Western blots were prepared
with extracts from M7-DEC1-16 cells that were uninduced (⫺) or induced (⫹) with doxycycline for 24 h and MCF7 cells that were untreated (⫺) and treated (⫹)
with 0.35 g/ml doxorubicin for 24 h. B, DEC1, but not DEC1-M and DEC1-R58P, inhibits cell proliferation. The growth rate of MCF7 cells that were uninduced
or induced to express DEC1, DEC1-M, and DEC1-R58P was measured over a 9-day period. MCF7 cells (MCF7-TR-7) that were treated with or without doxycycline
(an analog of tetracycline) were used as a control. C, DEC1, but not DEC1-M and DEC1-R58P, inhibits colony formation. Colony formation assay was performed
with MCF7 cells that were uninduced or induced to express DEC1, DEC1-M, or DEC1-R58P for 14 days. D, DEC1, but not DEC1-M and DEC1-R58P, induces G1
arrest. MCF7 cells were uninduced or induced to express DEC1, DEC1-M, or DEC1-R58P for 4 days and then used for BrdUrd/PI dual parameter analysis as
described under “Experimental Procedures.”

was not recognized by p53 (Fig. 2D, GAPDH panel). To analyze
the binding of p63 or p73, H1299 cells were uninduced or
induced to express Myc-tagged p63␤ or HA-tagged p73␤ and

2900 JOURNAL OF BIOLOGICAL CHEMISTRY

then used for ChIP assay. The p63-DNA complexes were
immunoprecipitated with anti-Myc antibody or rabbit IgG as a
control (Fig. 2E). The p73-DNA complexes were immunopreVOLUME 283 • NUMBER 5 • FEBRUARY 1, 2008
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expressed. To determine whether
cellular senescence induced by
overexpressed DEC1 is physiologically relevant, Western blot analysis
was performed to compare the levels of DNA damage-induced DEC1
and ectopic-expressed DEC1 in
MCF7 cells. We showed that the
level of DNA damage-induced
DEC1 was comparable with that of
ectopic-expressed DEC1 (Fig. 3A,
right panel).
Because cells that end at senescence must initially undergo cell
cycle arrest, growth rate analysis
and colony formation assay were
performed to examine whether
overexpression of DEC1 affects cell
proliferation. We found that overexpression of DEC1 inhibited the
proliferation of MCF7 cells over a
FIGURE 4. Overexpression of DEC1, but not mutant DEC1-M and DEC1-R58P, induces premature senes- 9-day period in both DEC1-expresscence. A, DEC1, but not mutant DEC1-M and DEC1-R58P, is capable of inducing premature senescence. MCF7 ing cell lines (Fig. 3B). As controls,
cells, which were uninduced or induced to express DEC1, DEC1-M, or DEC1-R58P for 8 days, were analyzed by doxycycline, DEC1-M, or DEC1SA-␤-galactosidase staining assay as described under “Experimental Procedures.” B, quantification of the percentage of SA-␤-galactosidase-positive colonies shown in A. See details in text. C, DEC1-induced senescence R58P had no effect on cell proliferaresults in up-regulation of hypophosphorylated p130. Western blots were prepared using extracts from MCF7 tion (Fig. 3B). Consistently, overexcells that were uninduced (⫺) or induced (⫹) to express DEC1 for 0, 1, 3, 5, or 7 days.
pression of DEC1, but not
doxycycline, DEC1-M, or DEC1cipitated with anti-HA antibody or mouse IgG as a control (Fig. R58P, inhibited the size and/or number of colonies (Fig. 3C).
2F). We found that both p63␤ and p73␤ bound to the p53-RE in Next, BrdUrd/PI dual parameter analysis was performed to
the DEC1 gene as well as to the one in the p21 gene (Fig. 2, E and characterize the cell cycle profile and showed that overexpresF, DEC1 and p21 panels). In contrast, the GAPDH promoter sion of DEC1 increased the percentage of cells in G1 phase,
was not recognized by p63␤ and p73␤ (Fig. 2, E and F, GAPDH concomitantly with a decrease in the percentage of cells in S
panels). In sum, these data indicate that DEC1 is a direct target (BrdUrd positive cells) and G phases (Fig. 3D). In contrast,
2
gene of the p53 family.
doxycycline, DEC1-M, and DEC1-R58P had no effect on
DEC1 Induces G1 Arrest and Initiates Cellular Senescence— BrdUrd incorporation (Fig. 3D). Taken together, we concluded
To test whether DEC1 is a downstream effector of p53 to medi- that the effect of DEC1 on cell proliferation is specific, and the
ate senescence, MCF7 cell line was chosen because it has a DNA binding activity of DEC1 is required for inducing cell
functional p53 pathway but lacks p16 (38). In addition, MCF7 cycle arrest.
cells undergo premature senescence upon treatment with
To test whether DEC1 is capable of inducing senescence,
doxorubicin (9, 10). Because p53 and p16 are the two major
SA-␤-galactosidase staining assay was performed. Microscopic
signaling pathways leading to cellular senescence (8, 12), the
analysis showed that the number of SA-␤-galactosidase-posiMCF7 cell line is an ideal system to address how p53 regulates
tive colonies was increased in DEC1-expressing cells compared
senescence. To analyze the biological activity of DEC1, multiple
with that in control and mutant DEC1-expressing cells. These
MCF7 cell lines, which inducibly express DEC1 and mutant
DEC1 proteins, DEC1-M and DEC1-R58P, under the control of SA-␤-galactosidase-positive colonies exhibited senescencea tetracycline-inducible promoter, were generated. DEC1-M like phenotypes, such as enlarged cell size, flattened morphollacks residues 53– 65 in the DNA binding domain and thus is ogy, and perinuclear blue (Fig. 4A). To quantify the extent of
transcriptionally inactive (21). Because of the deletion, DEC1-induced senescence, 150 –200 colonies were counted
DEC1-M has a lower molecular mass than its wild-type coun- and colonies containing ⱖ50% SA-␤-galactosidase-positive
terpart. DEC1-R58P has a point mutation at codon 58 (arginine cells were defined as senescent colonies. We found that overto proline) within the DNA binding domain, which diminishes expression of DEC1 markedly increased the percentage of
its DNA binding activity (21). Four representative cell lines senescent colonies in both M7-DEC1-6 and M7-DEC1-16 cell
were selected for further studies (Fig. 3A, left and middle pan- lines (Fig. 4B), whereas overexpression of DEC1-M or DEC1els) as follows: M7-DEC1 (clone 6 and 16) in which wild-type R58P had no effect (Fig. 4, A and B). We would like to note that
DEC1 can be inducibly expressed, M7-DEC1-M (clone 11) in a small number of MCF7 cells underwent spontaneous seneswhich DEC1-M can be inducibly expressed, and M7-DEC1- cence under normal cell culture conditions as reported previR58P (clone 2) in which DEC1-R58P can be inducibly ously (10). Similarly, overexpression of DEC1 was able to inhibit
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confirm that p53 is essential for
DNA damage-induced premature
senescence in MCF7 cells, p53 stable knockdown cell line, MCF7p53-KD, was utilized. As expected,
we found that p53 was stabilized by
treatment with doxorubicin in
MCF7 but not MCF7-p53-KD cells
(Fig. 5A, p53 panel). Similarly, p21
was induced by DNA damage in
MCF7 but not MCF7-p53-KD cells
(Fig. 5A, p21 panel). Next, SA␤-galactosidase staining assay
was performed and showed that
senescence-like phenotypes were
induced upon doxorubicin treatment in MCF7 cells but not MCF7p53-KD cells (Fig. 5B). Here, we
would like to note that the morphological change induced by DNA
damage in MCF7-p53-KD cells is
likely due to cell cycle arrest via a
p53-independent mechanism (15).
By quantifying SA-␤-galactosidasepositive colonies, we found that the
percentage of senescent cells was
markedly reduced upon p53-knockdown (Fig. 5C).
FIGURE 5. DEC1 is required for DNA damage-induced premature senescence. A, characterization of p53Because DEC1 is induced by
knockdown MCF7 cell lines. Western blots were prepared with extracts from MCF7 and MCF7-p53-KD cells that
were untreated (⫺) or treated (⫹) with 0.35 g/ml doxorubicin for 24 h. B, knockdown of p53 diminishes DNA DNA damage in a p53-dependent
damage-induced premature senescence. MCF7 or MCF7-p53-KD cells, which were cultured for 3 days and then
untreated (⫺) or treated (⫹) with 0.03 g/ml doxorubicin for 2 days, were analyzed by SA-␤-galactosidase manner and overexpression of
staining assay. C, quantification of SA-␤-galactosidase-positive colonies shown in B. D, generation of MCF7 cell DEC1 alone promotes senescence,
lines in which DEC1 is inducibly knocked down. Western blots were prepared with extracts from MCF7 cells that we examined whether DEC1 is
were uninduced (⫺) or induced (⫹) to express DEC1 siRNA for 3 days, followed by treatment with (⫹) or
without (⫺) 0.35 g/ml doxorubicin for 24 h. E, knockdown of DEC1 attenuates DNA damage-induced prema- required for DNA damage-induced
ture senescence. MCF7 cells, which were uninduced (⫺) or induced (⫹) to express DEC1 siRNA for 3 days and premature senescence. To test this,
then untreated (⫺) or treated (⫹) with 0.03 g/ml doxorubicin for 2 days, were analyzed by SA-␤-galactosidase MCF7 cell lines, in which endogestaining assay. F, quantification of SA-␤-galactosidase-positive colonies shown in E. G, knockdown of p53
diminishes DNA damage-induced up-regulation of hypophosphorylated p130 and pRb. Western blots were nous DEC1 is inducibly knocked
prepared with extracts from MCF7 and MCF7-p53-KD cells that were cultured for 3 days and then untreated (⫺) down via siRNA, were generated.
or treated (⫹) with 0.03 g/ml doxorubicin for 2 days. H, knockdown of DEC1 selectively diminishes up-regulation of hypophosphorylated p130 upon DNA damage. Western blots were prepared with extracts from Two representative cell lines (M7MCF7-DEC1-KD-1 cells that were uninduced (⫺) or induced (⫹) to express DEC1 siRNA for 3 days and then DEC1-KD-1 and -34) were selected
untreated (⫺) or treated (⫹) with 0.03 g/ml doxorubicin for 2 days.
for further studies. DEC1 was efficiently knocked down upon induccell proliferation and initiate premature senescence in U2OS tion of siRNA regardless of DNA damage (Fig. 5D, DEC1
panel). The levels of p53 and p21 were measured as positive
osteosarcoma cells (data not shown).
A recent study showed that p53 cooperates selectively with indicators of DNA damage (Fig. 5D, p53 and p21 panels). It has
p130 to induce cellular senescence when the p16/pRb pathway been shown that short hairpin vectors, which can trigger an
is disrupted (13). We speculated that DEC1 induces premature interferon response, would lead to up-regulation of 2⬘,5⬘-olisenescence through p130 because MCF7 cells are deficient in goadenylate synthetase (OAS1), a classic interferon target gene
p16. To test this, the phosphorylation status of p130 and pRb (41). To rule out the possibility that DEC1 siRNA elicits an
was examined, and it showed that the level of the active, interferon response, RT-PCR was performed to measure the
hypophosphorylated p130 was significantly increased by DEC1 induction of OAS1 and showed that OAS1 was not induced
(Fig. 4C, p130 panel), but hypophosphorylated pRb was only upon siRNA expression (data not shown). In addition,
slightly increased by DEC1 (Fig. 4C, pRb panel). Thus, we con- growth curve analysis and colony formation assay showed
cluded that overexpression of DEC1 alone is sufficient to pro- that DEC1-knockdown alone had no effect on cell proliferation in MCF7 cells (data not shown). Next, SA-␤-galactosidmote premature senescence.
DEC1 Is Required for DNA Damage-induced Premature ase staining assay was performed and showed that senesSenescence—Previous studies have shown that p53 plays a key cence-like phenotypes were induced by treatment with
role in premature senescence upon DNA damage (39, 40). To doxorubicin (Fig. 5, E and F), but the number of SA-␤-galac-
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tosidase-positive cells was substantially reduced by DEC1knockdown (Fig. 5, E and F).
To further analyze the effect of p53- and DEC1-knockdown
on DNA damage-induced senescence, we examined the phosphorylation status of p130. We found that the level of
hypophosphorylated p130 was significantly increased by treatment with doxorubicin in MCF7 but not in MCF7-p53-KD cells
(Fig. 5G, p130 panel). Likewise, the level of hypophosphorylated p130 was reduced by DEC1-knockdown (Fig. 5H, p130
panel). Interestingly, we found that hypophosphorylated pRb
was altered upon p53-knockdown, but it was not affected by
DEC1-knockdown (Fig. 5, G and H, pRb panels). These data
indicate that DEC1 is one of the effectors downstream of p53 in
DNA damage-induced senescence.
p53 Modulates, but Is Not Required for, DEC1-induced Premature Senescence—Given the importance of p53 in premature
senescence upon DNA damage (39, 40), it is likely that p53 plays
a role in DEC1-induced premature senescence. To test this, we
generated multiple MCF7 cell lines in which p53 was stably
knocked down and DEC1 is inducibly expressed. Two representative cell lines (M7-(p53-KD)-DEC1-7 and -12) were
selected for future studies (Fig. 6A). Western blot analysis
showed that comparable levels of DEC1 were inducibly
expressed in p53-proficient and -knockdown cell lines (Fig. 6A,
DEC1 panel). However, unlike in M7-DEC1-6 and M7FEBRUARY 1, 2008 • VOLUME 283 • NUMBER 5

DEC1-16 cell lines, no basal levels of p53 were detected in M7(p53-KD)-DEC1-7 and M7-(p53-KD)-DEC1-12 cell lines (Fig.
6A, p53 panel). Next, we examined the activity of DEC1 in the
absence of p53. We found that the ability of DEC1 to inhibit cell
proliferation, as measured by growth rate, colony formation,
and cell cycle profile, was not significantly affected by p53knockdown (data not shown). We also found that overexpression of DEC1 was still capable of inducing senescence in p53knockdown MCF7 cells, although this effect was much weaker
than that in p53-proficient MCF7 cells (Fig. 6B). These data
suggest that DEC1 functions downstream of p53 to initiate cellular senescence and p53 mediates, but is not necessarily
required for, DEC1-induced premature senescence.
p21 Is Not Required for DEC1-induced Premature Senescence—
p21 was first identified as an overexpressed gene in senescent
cells (42). It has been shown that p21 is capable of inducing
premature senescence in p53-null H1299 cells (43). To examine
whether p21 plays a role in DEC1-induced senescence, multiple
MCF7 cell lines, in which p21 was stably knocked down and
DEC1 is inducibly expressed, were generated. Two representative cell lines, M7-(p21-KD)-DEC1-12 and M7-(p21-KD)DEC1-16, are shown in Fig. 7A. Compared with p21-proficient
MCF7 cells (M7-DEC1-16), p21 was efficiently knocked down
in these two cell lines (Fig. 7A, p21 panel). In addition, a comparable level of DEC1 was expressed in both p21-proficient and
-knockdown MCF7 cells (Fig. 7A, DEC1 panel). Next, growth
rate and cell cycle profile analyses were performed and showed
that cell proliferation was inhibited by DEC1 regardless of p21
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FIGURE 6. p53 modulates, but is not required for, DEC1-induced premature senescence. A, generation of MCF7 cell lines in which p53 was stably
knocked down and DEC1 is inducibly expressed. B, overexpression of DEC1 is
capable of inducing premature senescence in p53-knockdown MCF7 cells.
MCF7 and MCF7-p53-KD cells, which were uninduced or induced to express
DEC1 for 8 days, were used for SA-␤-galactosidase staining assay. The percentage of SA-␤-galactosidase-positive colonies was analyzed as in Fig. 4B.

FIGURE 7. p21 is not required for DEC1-induced premature senescence.
A, generation of MCF7 cell lines in which p21 was stably knocked down and
DEC1 is inducibly expressed. B, overexpression of DEC1 is capable of inducing
premature senescence in p21-knockdown MCF7 cells. SA-␤-galactosidase
staining analysis was performed as in Fig. 6B.

DEC1 Is a Mediator of p53-dependent Premature Senescence
status (data not shown). Furthermore, the efficiency of DEC1 to
promote premature senescence was not affected upon p21knockdown (Fig. 7B). Therefore, we concluded that p21 is not
required for the proper function of DEC1 to initiate senescence.
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DISCUSSION
DEC1 belongs to the bHLH family of transcription factors
and is able to suppress cell proliferation in multiple cell lines
(18, 20, 21). Interestingly, a recent study has showed that oncogene K-rasV12-induced senescence is correlated with DEC1
up-regulation (22), but whether DEC1 is required for senescence has not been determined. Here we found that DEC1 is
induced by p53 and DNA damage in a p53-dependent manner.
We also showed that p53 binds to the promoter of the DEC1
gene and transcriptionally regulates DEC1 through a potential
p53-responsive element found in the DEC1 promoter. Moreover, we showed that overexpression of DEC1 alone initiates G1
arrest and senescence, and knockdown of DEC1 attenuates
DNA damage-induced premature senescence. Furthermore,
the phosphorylation status of p130 is altered during DEC1-mediated senescence, consistent with previous studies that p53mediated and DNA damage-induced senescence is primarily
through p130 (13, 14). Taken together, we concluded that
DEC1 is one of the effectors downstream of p53 to promote
premature senescence.
It has been shown that p53 and p16 are the two major signaling pathways leading to cellular senescence, thus targeting p53
and p16 would circumvent oncogenic ras-induced senescence
(8). However, downstream effectors of p53 that may promote
cellular senescence are little known. The expression of promyelocytic leukemia protein is found to be regulated by p53 (44).
In turn, promyelocytic leukemia is capable of inducing premature senescence by stabilizing p53 via promoting p53 acetylation (45). In contrast, deacetylation of p53 antagonizes promyelocytic leukemia-induced premature senescence (46). These
data indicate that p53 plays an important role downstream of its
target during senescence. Interestingly, here we found that
overexpression of DEC1 is able to induce premature senescence
in p53-knockdown cells albeit to a less extent (Fig. 6B). This
suggests that p53 modulates, but is not required for, DEC1induced cellular senescence. In addition, a well studied p53 target, p21, is capable of initiating premature senescence in p53null H1299 cells (43). However, the efficiency of DEC1 to
promote premature senescence was not affected upon p21knockdown (Fig. 7B). Taken together, it is possible that DEC1
and p21 may independently elicit cellular senescence downstream of p53.
As a transcription factor, DEC1 may directly regulate some
targets involved in cell cycle arrest and senescence. To uncover
these potential targets of DEC1, an Affymetrix GeneChip assay
was performed by using M7-DEC1-16, which was uninduced or
induced to express DEC1. Several potential target genes were
identified, including epithelium-specific ETS gene-2 (ELF5/
ESE2) and -3 (EHF/ESE3). ELF5 and EHF belong to the Ets
family of transcription factors and may be involved in regulating cell proliferation, differentiation, and tumorigenesis (47,
48). Moreover, it has been reported that Ets family proteins,
Ets1 and Ets2, can activate the p16 promoter, and an increase in

Ets1 was observed in senescent human diploid fibroblasts (49).
Therefore, it is possible that ELF5 and EHF are downstream
targets of DEC1 to induce cell cycle arrest and/or cellular senescence. Future studies to identify and confirm potential DEC1
targets involved in senescence would provide an insight into the
mechanism by which DEC1 mediates senescence.
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